Engineered nanoparticles to enhance natural killer cell activity towards onco-immunotherapy: a review
Archives of Pharmacal Research, ISSN: 1976-3786, Vol: 43, Issue: 1, Page: 32-45
2020
- 27Citations
- 36Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations27
- Citation Indexes27
- 27
- CrossRef4
- Captures36
- Readers36
- 36
Review Description
Natural killer (NK) cells have emerged as a potent alternative immunotherapeutic approach to T cell therapy for cancer. Despite promising results from preclinical and clinical studies, numerous challenges have limited the application of NK cell-based therapy, including poor expansion of NK cells in vitro, their short in vivo life span, time-intensiveness, treatment complexities, and the cost burden of the treatment. Recent advancements in the development of immune cell-delivering nanosystems have led to promising strategies to overcome these limitations and enhance NK cell toxicity towards cancer cells. This review first summarizes the biological roles of NK cells and their tumoricidal mechanisms. NK cells, in the context of the immune system and the tumor microenvironment, have reportedly provided novel insights into specific therapeutic targets. Eventually, various strategies targeting NK cells using nanoplatforms to modulate the NK cell responses for effective cancer immunotherapy are described herein. Altogether, this review discusses the potential of nanotechnology in advancements in NK cell-based onco-immunotherapy.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85078472690&origin=inward; http://dx.doi.org/10.1007/s12272-020-01218-1; http://www.ncbi.nlm.nih.gov/pubmed/31993969; http://link.springer.com/10.1007/s12272-020-01218-1; https://dx.doi.org/10.1007/s12272-020-01218-1; https://link.springer.com/article/10.1007/s12272-020-01218-1
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know